VPH2

Heart failure accounts for almost a quarter of all admissions to hospital for cardiovascular events, has a high mortality (median survival around 18 months), and places a great burden on all healthcare systems, with estimated direct costs of £905m (1350m) in the United Kingdom in 2000, 2% of total NHS expenditure.

Virtual pathological heart of the virtual physiological human (VPH2) project aims to develop a patient-specific computational modelling and simulation of the human heart to assist the cardiologist and the cardiac surgeon in defining the severity and extent of disease in patients with post-ischemic Left Ventricular Dysfunction (LVD), with or without ischemic mitral regurgitation (IMR). Specific computational methods will allow clinical decision making and planning of the optimal treatment for left ventricle-valve repair. The goal is not only to deploy a fully validated technology to partner clinical institutions, but also to develop a sustainable business model associated to it.

The associated technological aim of the project is to deliver the most advanced software application framework for the development of computer-aided medicine in cardiology and cardiac surgery available in the world, going beyond the state of the art of available models.

This goal will be achieved by integrating some of the leading Open Source software in the area of computer-aided medicine and of computational bioengineering. This framework will be used by VPH2 to realise its objectives, but also by any other future project (academic or industrial) aiming to improve or extend VPH2 objectives.

For further information, please visit:
http://www.vph2.eu

Project co-ordinator:
GMD - Gesellschaft für Medizinische Datenverarbeitung mbH

Partners:

  • Intercon Sp. Z o.o. (Poland)
  • Euro PMS ltd (United Kingdom)
  • Sorin Biomedica Cardio S.r.l. (Italy)
  • SCS S.r.l. (Italy)
  • EREYNITIKO AKADIMAIKO INSTITOUTO TECHNOLOGIAS YPOLOGISTON (Greece)
  • Westfälische Wilhelms-Universität Münster (Germany)
  • PATMOS S.r.l. (Italy)
  • Aminio AB (Sweden)
  • Ecole Polytechnique Fédérale de Lausanne (Switzerland)
  • University of Bedfordshire (United Kingdom)
  • Regione Lombardia (Italy)
  • Quality & Reliability S.A (Greece)

Timetable: from 07/2008 - to 06/2011

Total cost: € 5.180.000

EC funding: € 3.780.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...